[1] De Jonge H,Naesens M,Kuypers DR.New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drugmonitoring in solid organ transplantation.Ther. Drug Monit.2009;31(4):416-435.
[2] Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.Am J Health Syst Pharm.2006;63(23): 2340-2348.
[3] Staatz CE,Goodman LK,Tett SE.Effect of CYP3Aand ABCB1single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.Clin Pharmacokinet.2010;49(3):141-175.
[4] 胡永芳,翟所迪,邱雯. CYP3A5*3和CYP3A4*18B基因多态性对肾移植患者环孢素药代动力学的影响[J].中国药理学通报, 2009,25(3):378-382.
[5] Kreutz R, Zurcher H, Kain S, et al. The effect of variable CYP3A5 expressionon cyclosporine dosing,blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics.2004;14(10):665-671.
[6] Amundsen R,Asberg A,Ohm IK,et al.Cyclosporine A and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in virtio.Drug Metab Dispos.2012;40(4):655-661.
[7] Hesselink DA,van Gelder,van Schalk RH,et al.Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and influence of ethnicity and genetic polymorphisms in the MDR-1,CYP3A4,and CYP3A5 genes.Clin Pharmacol Ther.2004;76(6):545-556.
[8] Elens L, Bouamar R, Hesselink DA,et al.The new CYP3A4 intron 6C>T polymorphism (CYP3A4*22) is associated with an increase risk of delayed graft function and worse renal function in cyclosporine-treated kidey transplant patients. Pharmacognet Genomics.2012;22(5):373-380.
[9] Meng XG, Guo CX, Feng GQ, et al. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post renal transplant recipients in China.Acta Pharmacol Sinica. 2012;33(12):1563-1570.
[10] Bouamar R,Hesselink DA,van Schaik RH ,et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit.2011;33(2):178-184.
[11] Singh R,Kesarwani P,Srivastava A,et al.ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.Arch Med Res. 2008;39(7):695-701.
[12] 辛华雯,刘慧明,李元启,等.ABCB1基因多态性对肾移植受者环孢素血浓度的影响[J].中国药师,2013,16(2):173-178.
[13] Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.Drug Metab Pharmacokinet. 2007;22(5):328-335.
[14] 蔡文娥,农江,孙煦勇.CYP3A5基因多态性对肝移植受者血他克莫司浓度影响的研究进展[J].中华器官移植杂志,2014,35(3): 185-187.
[15] Lamba JK, Lin YS, Schuetz EG,et al.Genetic contribution to variable human CYP3A-mediated metabolism.Adv Drug Deliv Rev.2002;54(10):1271-1294.
[16] 何霞,童荣生.CYP3A4和CYP3A5基因多态性对汉族肾移植患者他克莫司血药浓度的影响[J].中国药师,2013,16(4): 497-501.
[17] Hustert E,Habcrl M.Burk O.et al.The genetic determinants of the CYP3A5 polymorphism.Pharmacogenetics.2001;11(9): 773-779.
[18] Zhang X, Liu ZH, Zheng JM, et al.Influence of CYP3A5 and MDRl polymorphisms on tacrolimus concentration in the early stage after renal transplantation.ClinTransplant.2005;19(5): 638-643.
[19] 徐芳,马潞林,付燕,等.CYP 3A5*3基因多态性对肾移植术后他克莫司药代动力学的影响[J].中国临床药理学杂志,2008,24(3): 207-211.
[20] Roy JN, Barama A, Poirier C, et al. Cyp3A4、Cyp3A5.and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Pharmacogenet Genomics.2006; 16(9):659-665.
[21] 丰贵文,郭涛,李金锋,等.CYP3A5基因多态性对肾移植受者他克莫司个体化用药的指导[J].中华器官移植杂志,2013,34(11): 647-650.
[22] Elens L, van Schaik RH, Panin N, et al.Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics.2011;12(10): 1383-1396.
[23] Elens L, van Gelder T, Hesselink DA, et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.Pharmacogenomics.2013; 14(1):47-62.
[24] 陈有娥.CYP3A4,CYP3A5,MDR1基因多态性与他克莫司个体间差异相关性的研究进展[J].中国医药指南,2013,11(14): 71-73.
[25] Shi XJ, Geng F, Jiao Z, et al. Association of ABCBl, CYP3A4*18B and CYP3A5*3 genotypes with thepharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmaeokinetie analysis. J Clin Pharm Ther.2011;36(5):614-624.
[26] de Jonge H, de Loor H, Verbeke K,et al. In vivo CYP3A4 activity, CYP3A5 Genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Articles.2012; 92 (3):366-375.
[27] 李丹滢,陈燕华,方芸.CYP3A4/5单倍型将影响他克莫司血药谷浓度[J].国际药学研究杂志,2013,40(3):350-354.
[28] 何霞,童荣生.CYP3A4和CYP3A5基因多态性对汉族肾移植患者他克莫司血药浓度的影响[J].中国药师,2013,16(4):497-501.
[29] 林玲,宋文利,沈中阳,等.肾移植受者CYP3 A5*3和CYP3 A4*1 8 B对他克莫司药动学的影响[J].中华器官移植杂志, 2012,33(4): 220-224.
[30] De Jonge H, Metalidis C, Naesens M, et al. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011;12(9):1281-1291.
[31] 梁海伟,郭宣麟.孕烷X受体的研究进展[J].生物技术通讯, 2013, 24(3):441-445.
[32] Barraclough KA,Isbel NM,Lee KJ,et al.NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation.Transplantation.2012; 94(10):1025-1032.
[33] Herrero MJ, Sanchez-Plumed J, Galiana M, et al.Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant.Proc.2010;42(8):3134-3136.
[34] Lopez-Montenegro Soria MA, Kanter Berga J, Beltran Catalan S, et al. Genetic polymorphisms and individualized tacrolimus dosing. Transplant Proc. 2010;42(8):3031-3033.
[35] Wu P, Ni X, Wang M, et al.Polymorphisms in CYP3A5*3and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Ann. Transplant. 2011;16(1):54-60.
[36] Rong G, Jing L, Deng-Qing L, et al. Influence of CYP3A5and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.Transplant Proc.2010;42(9):3455-3458.
[37] Hawwa AF,McKiernan PJ,Shields M,et al.Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.Br J Clin. Pharmacol.2009;68(3):413-421.
[38] Yamauchi A,Ieiri I,Kataoka Y,et al.Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1(MDR1) gene. Transplantation. 2002;74(4):571-572.
[39] Cattaneo D, Ruggenenti P, Baldelli S, et al.ABCB1genotypes predict cyclosporinerelated adverse events and kidney allograft outcome. J. Am. Soc.Nephrol.2009;20(6):1404-1415.
[40] Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and metaanalysis of randomized trials. Transplantation.2006;81(9):1234-1248.
[41] Merkel S, Mogilevskaja N, Mengel M, et aL.Side effects of sirolimus. Transplant Proc.2006;38(3):714-715.
[42] Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann. Pharmacother. 2000;34(9):1044-1055.
[43] Djebli N,Rousseau A,Rerolle JP,et al.Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modeling in kidney transplant recipients.Clin Pharmacokinet. 2006;45(11):1135-1148.
[44] Kniepeiss D, Renner W, Trummer O, et al.The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.Clin Transplant. 2011; 25(1):146-150.
[45] 廖珂,敖建华,赵冠人,等.汉族肾移植受者稳定期CYP3 A5*3基因多态性与血西罗莫司浓度的相关性[J].中华器官移植杂志, 2013, 34(5):260-264.
[46] 李炎唐,张玉海.新世纪肾脏移植学[M].北京:军事医学科学出版社,2001:153-153.
[47] 张伟霞.基因多态性对霉酚酸药动与药效学影响的研究[D]上海:上海交通大学药学系,2010.
[48] Pasanen MK,Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1.Pharmacogenomics.2008; 9(1):19-33.
[49] Bouamar R, Hesselink DA, van Schaik RH, et al. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1in renal transplant recipients.Pharmacogenet Genomics.2012;22(6):399-407.
[50] Pazik J, O?dak M, D?browski M, et al.Association of UDP-glucuronosyltransferase 1A9(UGT1A9) gene polymorphism with kidney allograft function.Transplant. 2011; 16(4):69-73. |